{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:22:16Z","timestamp":1791181336570,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacology Biochemistry and Behavior"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1016\/j.pbb.2011.08.001","type":"journal-article","created":{"date-parts":[[2011,8,7]],"date-time":"2011-08-07T04:18:01Z","timestamp":1312690681000},"page":"284-288","source":"Crossref","is-referenced-by-count":25,"title":["Chronic agomelatine and fluoxetine induce antidepressant-like effects in H\/Rouen mice, a genetic mouse model of depression"],"prefix":"10.1016","volume":"100","author":[{"given":"Malika","family":"El Yacoubi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Dubois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Gabriel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Moca\u00ebr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marie","family":"Vaugeois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pbb.2011.08.001_bb0005","first-page":"21","article-title":"Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project","author":"Alonso","year":"2004","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"10.1016\/j.pbb.2011.08.001_bb0010","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s00210-003-0751-2","article-title":"New selective ligands of human cloned melatonin MT1 and MT2 receptors","volume":"367","author":"Audinot","year":"2003","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.pbb.2011.08.001_bb0015","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.pnpbp.2005.04.032","article-title":"Antidepressant action of agomelatine (S 20098) in a transgenic mouse model","volume":"29","author":"Barden","year":"2005","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pbb.2011.08.001_bb0020","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1056\/NEJMra073096","article-title":"Major depressive disorder","volume":"358","author":"Belmaker","year":"2008","journal-title":"N Engl J Med"},{"issue":"Suppl. 1","key":"10.1016\/j.pbb.2011.08.001_bb0025","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S1389-9457(08)70010-8","article-title":"Insomnia and depression","volume":"9","author":"Benca","year":"2008","journal-title":"Sleep Med"},{"key":"10.1016\/j.pbb.2011.08.001_bb0030","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1097\/FBP.0b013e3280116e5c","article-title":"Antidepressant-like effects of agomelatine (S 20098) in the learned helplessness model","volume":"17","author":"Bertaina-Anglade","year":"2006","journal-title":"Behav Pharmacol"},{"key":"10.1016\/j.pbb.2011.08.001_bb0035","first-page":"126","article-title":"Antidepressant-like activity of S 20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors","volume":"29","author":"Bourin","year":"2004","journal-title":"J Psychiatry Neurosci"},{"key":"10.1016\/j.pbb.2011.08.001_bb0040","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0091-3057(01)00701-8","article-title":"Induction of hyperlocomotion in mice exposed to a novel environment by inhibition of serotonin reuptake. A pharmacological characterization of diverse classes of antidepressant agents","volume":"71","author":"Brocco","year":"2002","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.pbb.2011.08.001_bb0045","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.pbb.2009.08.008","article-title":"Direct and indirect 5-HT receptor agonists produce gender-specific effects on locomotor and vertical activities in C57 BL\/6J mice","volume":"94","author":"Brookshire","year":"2009","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.pbb.2011.08.001_bb0170","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/nrd3274","article-title":"Agomelatine, the first melatonergic antidepressant: discovery, characterization and development","volume":"9","author":"de Bodinat","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.pbb.2011.08.001_bb0050","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.coph.2006.11.002","article-title":"Genetic rodent models of depression","volume":"7","author":"El Yacoubi","year":"2007","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.pbb.2011.08.001_bb0055","doi-asserted-by":"crossref","first-page":"6227","DOI":"10.1073\/pnas.1034823100","article-title":"Behavioral, neurochemical, and electrophysiological characterization of a genetic mouse model of depression","volume":"100","author":"El Yacoubi","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pbb.2011.08.001_bb0060","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0896-6273(00)00112-4","article-title":"Major depressive disorder","volume":"28","author":"Fava","year":"2000","journal-title":"Neuron"},{"key":"10.1016\/j.pbb.2011.08.001_bb0065","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.smrv.2007.09.003","article-title":"Sleep-specific mechanisms underlying posttraumatic stress disorder: integrative review and neurobiological hypotheses","volume":"12","author":"Germain","year":"2008","journal-title":"Sleep Med Rev"},{"issue":"Suppl 2","key":"10.1016\/j.pbb.2011.08.001_bb0175","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2165\/11318650-000000000-00000","article-title":"Clinical studies on the efficacy of agomelatine on depressive symptoms","volume":"23","author":"Goodwin","year":"2009","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pbb.2011.08.001_bb0070","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.4088\/JCP.08m04548","article-title":"Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial","volume":"70","author":"Goodwin","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pbb.2011.08.001_bb0075","doi-asserted-by":"crossref","first-page":"109","DOI":"10.4088\/JCP.09m05347blu","article-title":"Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline","volume":"71","author":"Kasper","year":"2007","journal-title":"J Clin Psychiatry"},{"issue":"Suppl. 2","key":"10.1016\/j.pbb.2011.08.001_bb0080","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2165\/11318660-000000000-00000","article-title":"Agomelatine: efficacy at each phase of antidepressant treatment","volume":"23","author":"Kennedy","year":"2009","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pbb.2011.08.001_bb0085","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.euroneuro.2005.09.002","article-title":"Placebo-controlled trial of agomelatine in the treatment of major depressive disorder","volume":"16","author":"Kennedy","year":"2006","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.pbb.2011.08.001_bb0090","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/00004850-200209000-00004","article-title":"Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study","volume":"17","author":"Loo","year":"2002","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.pbb.2011.08.001_bb0095","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002130100694","article-title":"Sensitivity to the effects of pharmacologically selective antidepressants in different strains of mice","volume":"155","author":"Lucki","year":"2001","journal-title":"Psychopharmacol (Berl)"},{"key":"10.1016\/j.pbb.2011.08.001_bb0180","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.pharmthera.2005.11.006","article-title":"Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application","volume":"110","author":"Millan","year":"2006","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.pbb.2011.08.001_bb0100","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1124\/jpet.103.051797","article-title":"The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways","volume":"306","author":"Millan","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pbb.2011.08.001_bb0105","first-page":"661","article-title":"Efficacy of agomelatine, a MT1\/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder","volume":"10","author":"Olie","year":"2007","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.pbb.2011.08.001_bb0110","first-page":"1","article-title":"Behavioural and neuroplastic effects of the new-generation antidepressant agomelatine compared to fluoxetine in glucocorticoid receptor-impaired mice","author":"Paizanis","year":"2009","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.pbb.2011.08.001_bb0185","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1017\/S1461145709990514","article-title":"Behavioural and neuroplastic effects of the new-generation antidepressant agomelatine compared to fluoxetine in glucocorticoid receptor-impaired mice","volume":"13","author":"Pa\u00efzanis","year":"2010","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.pbb.2011.08.001_bb0115","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/BF02244188","article-title":"An animal model of anhedonia: attenuation of sucrose consumption and place preference conditioning by chronic unpredictable mild stress","volume":"104","author":"Papp","year":"1991","journal-title":"Psychopharmacol (Berl)"},{"key":"10.1016\/j.pbb.2011.08.001_bb0120","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/sj.npp.1300091","article-title":"Effect of agomelatine in the chronic mild stress model of depression in the rat","volume":"28","author":"Papp","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pbb.2011.08.001_bb0125","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/0031-9384(93)90351-F","article-title":"Chronic mild stress-induced anhedonia: greater effect in a genetic rat model of depression","volume":"54","author":"Pucilowski","year":"1993","journal-title":"Physiol Behav"},{"key":"10.1016\/j.pbb.2011.08.001_bb0130","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1177\/074873098128999907","article-title":"Entrainment of rat circadian rhythms by the melatonin agonist S-20098 requires intact suprachiasmatic nuclei but not the pineal","volume":"13","author":"Redman","year":"1998","journal-title":"J Biol Rhythms"},{"key":"10.1016\/j.pbb.2011.08.001_bb0135","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.bbr.2005.06.016","article-title":"Behavioral characteristics of rats predisposed to learned helplessness: reduced reward sensitivity, increased novelty seeking, and persistent fear memories","volume":"164","author":"Shumake","year":"2005","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.pbb.2011.08.001_bb0140","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/0278-5846(87)90002-9","article-title":"The automated Tail Suspension Test: a computerized device which differentiates psychotropic drugs","volume":"11","author":"Steru","year":"1987","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pbb.2011.08.001_bb0145","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1038\/sj.npp.1300532","article-title":"Stress-induced anhedonia in mice is associated with deficits in forced swimming and exploration","volume":"29","author":"Strekalova","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pbb.2011.08.001_bb0150","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1126\/science.1117571","article-title":"Alterations in 5-HT1B receptor function by p11 in depression-like states","volume":"311","author":"Svenningsson","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.pbb.2011.08.001_bb0155","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1081\/CBI-100107514","article-title":"S20098 affects the free-running rhythms of body temperature and activity and decreases light-induced phase delays of circadian rhythms of the rat","volume":"18","author":"Tuma","year":"2001","journal-title":"Chronobiol Int"},{"key":"10.1016\/j.pbb.2011.08.001_bb0160","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1007\/BF01954918","article-title":"Antidepressant drugs can slow or dissociate circadian rhythms","volume":"38","author":"Wirz-Justice","year":"1982","journal-title":"Experientia"},{"key":"10.1016\/j.pbb.2011.08.001_bb0165","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1021\/jm00086a018","article-title":"Novel naphthalenic ligands with high affinity for the melatonin receptor","volume":"35","author":"Yous","year":"1992","journal-title":"J Med Chem"}],"container-title":["Pharmacology Biochemistry and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305711002656?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305711002656?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,30]],"date-time":"2018-11-30T21:55:31Z","timestamp":1543614931000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091305711002656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["S0091305711002656"],"URL":"https:\/\/doi.org\/10.1016\/j.pbb.2011.08.001","relation":{},"ISSN":["0091-3057"],"issn-type":[{"value":"0091-3057","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}